DiaMedica Therapeutics (DMAC) Other financing activities (2018 - 2026)
DiaMedica Therapeutics' (DMAC) quarterly Other financing activities came in at $135000.0 in Q2 2026, down 17.18% on a YoY basis from $163000.0 in Q2 2025, and down 67.86% quarter-over-quarter from $420000.0 in Q1 2026.
Powered by 
Analysis
DiaMedica Therapeutics (DMAC) Other financing activities (2018 - 2026) Analysis & Trends
DiaMedica Therapeutics (DMAC) has reported Other financing activities for 6 consecutive years, with $135000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Other financing activities fell 17.18% year-over-year to $135000.0; the trailing twelve-month figure through Jun 2026 stood at $1.3 million (up 157.31% YoY), and the FY2025 full-year result was $1.0 million, up 292.19% from the prior year.
- Other financing activities slipped to $135000.0 in Q2 2026 per DMAC's latest filing, from $420000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $465000.0 in Q3 2025 and bottomed at $7000.0 in Q2 2024.
- Historically, Other financing activities has averaged $201666.7 across 3 years, with a median of $135000.0 in 2026.
- The sharpest annual moves came in 2025 and 2026: Other financing activities soared 2228.57% in 2025, then retreated 17.18% in 2026.
- Over 3 years, Other financing activities stood at $123000.0 in 2024, then surged by 129.27% to $282000.0 in 2025, then sank by 52.13% to $135000.0 in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered $135000.0, $420000.0, and $282000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | DiaMedica Therapeutics | 364.00 Mn | 364.00 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 135,000.00 |
| Mar 31, 2026 | 420,000.00 |
| Dec 31, 2025 | 282,000.00 |
| Sep 30, 2025 | 465,000.00 |
| Jun 30, 2025 | 163,000.00 |
| Mar 31, 2025 | 94,000.00 |
| Dec 31, 2024 | 123,000.00 |
| Sep 30, 2024 | 126,000.00 |
| Jun 30, 2024 | 7,000.00 |
| Mar 31, 2021 | 244,000.00 |
| Dec 31, 2020 | 29,000.00 |
| Mar 31, 2020 | 16,000.00 |
| Dec 31, 2018 | 86,000.00 |
| Sep 30, 2018 | 31,000.00 |
| Jun 30, 2018 | 6,000.00 |
| Mar 31, 2018 | 484,000.00 |